MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Two-year Outcomes of Restless Legs Syndrome Following Globus Pallidus Interna Deep Brain Stimulation for Parkinson’s Disease

    J. Zuzuarregui, A. Mahes, A. Wiltshire, S. Wang, M. San Luciano (San Francisco, USA)

    Objective: This study evaluated two-year outcomes of Restless Legs Syndrome (RLS) in a cohort of patients with Parkinson’s disease (PD) who underwent deep brain stimulation…
  • 2026 International Congress

    Aggregation – Dependent Effects of Wild-Type and Mutant α-Synuclein on Synaptic Membrane Fusion

    M. Sriram, D. Rege, A. Das, R. Nellikka, D. Das (Mumbai, India)

    Objective: 1. What is the endogenous form of ⍺-Synuclein in various cell types?2. How do WT ⍺-Synuclein monomer and aggregates affect presynaptic membrane fusion and the…
  • 2026 International Congress

    Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide

    M. Vale, D. Lopes, H. Brigas, J. Holenz (Coronado, Portugal)

    Objective: To review the safety data of opicapone (OPC) after 10 years of worldwide marketing experience. Background: OPC, a third-generation COMT inhibitor, is approved as…
  • 2026 International Congress

    Peripheral neuropathy (NP) in advanced Parkinson’s disease (PD) patients treated with continuous subcutaneous foslevodopa/foscarbidopa (fLD/fCD)

    H. Salhi, A. Gravier, V. Garbage, B. Cormier, A. Dormeuil, A. Petit, A. Zayed, V. Perrain, T. Gendre, P. Remy (Creteil, France)

    Objective: To assess peripheral NP occurrence and clinico-electrophysiological features in patients with advanced PD patients treated with continuous subcutaneous fLD/fCD. Background: Continuous subcutaneous fLD/fCD is effective…
  • 2026 International Congress

    Exposure-Response Analysis of Glovadalen in the ATLANTIS Phase II Study: Trial Simulation Explains Dose-Response for OFF Time in Parkinson’s

    D. Menshykau, M. Biagioni, C. Beuter, C. Legendre, A. Benoit, L. Vroye, B. Klünder, M. Faisal, S. Leach, R. Nicholl, H. Naik (Monheim am Rhein, Germany)

    Objective: This analysis characterized the exposure-response (E-R) relationship of glovadalen (UCB0022) in the ATLANTIS Phase-IIa proof-of-concept study, to understand the apparent lack of dose-response for…
  • 2026 International Congress

    Astrocyte Derived Extracellular Vesicle miR 210 Expression in Exenatide Treated Patients with Parkinson’s Disease

    A. Keshavaprasad, I. Markaki, P. Svenningsson, S-B. Catrina, X. Zheng (Linköping, Sweden)

    Objective: To investigate miR‑210 expression in astrocyte‑derived extracellular vesicles (ADEVs) from individuals with PD treated with Exenatide versus placebo. Background: Hypoxic stress profoundly alters neuronal…
  • 2026 International Congress

    MobilityAPP: A randomized-controlled trial evaluating 
gait-focused physiotherapy in Parkinson’s disease and 
atypical parkinsonian syndromes

    V. Sidoroff, C. Raccagni, H. Moradi, G. Prigent, F. Jagusch, I. Teckenburg, M. Giraitis, E. Schoenfeldt Reichmann, J. Ndayisaba, G. Göbel, K. Seppi, F. Krismer, D. Benninger, J. Winkler, B. Eskofier, J. Klucken, K. Aminian, A. Ionescu, S. Sapienza, H. Gaßner (Innsbruck, Austria)

    Objective: Effect on gait and balance of gait-focused physiotherapy compared to standard-of-care physiotherapy in patients with MSA, PSP and PD. Background: Physiotherapy is a crucial element…
  • 2026 International Congress

    Automated Speech Analysis for the Differentiation of Multiple System Atrophy from Parkinson’s Disease in an English-Speaking Cohort

    E. Ní Chonchúir, C. Espinoza Vinces, X. Yang, C. O'Keeffe, J. Inocentes, A. Gill, C. Fearon, R. Reilly (Dublin, Ireland)

    Objective: The aim of this pilot study was to determine whether automatically extracted speech features, derived from targeted speech tasks, can differentiate Multiple System Atrophy…
  • 2026 International Congress

    DBS withdrawal syndrome in Parkinson’s disease: Clinical features and outcomes of two new cases

    E. Ottela, J. Rönkä, V. Kaasinen, J. Joutsa (Turku, Finland)

    Objective: To report two cases of deep brain stimulation (DBS) withdrawal syndrome in Parkinson’s disease (PD), including one without typical risk factors. Background: DBS withdrawal…
  • 2026 International Congress

    NPC2 is an Allele-Specific Modifier of GBA1-Associated Parkinson’s Disease Risk

    J. Kim, R. de Paula, C. Shaw, J. Shulman (Houston, USA)

    Objective: To identify rare variant modifiers of GBA1-associated Parkinson's disease (PD) penetrance among lysosomal storage disorder (LSD) genes. Background: GBA1 is the most common large-effect…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 208
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley